EDICREA®

Lyon and New York, January 15th 2016 - The MEDICREA Group (Alternext Paris: FR0004178572 - ALMED), which specializes in the development and manufacturing of innovative surgical technologies for the treatment of spinal pathologies, announces its financial calendar for the year ending December 31st 2016. Publications will be submitted after market. This calendar is provided for information only and may be subject to change.

2016 FINANCIAL CALENDAR

•	2015 Annual results	April, 6 th 2016
	and 2016 First Quarter sales	
•	Annual General Meeting	June, 7 th 2016
•	2016 Half Year sales	July, 7 th 2016
•	2016 Half Year results	September, 8th 2016
•	2016 Third Quarter sales	October, 6 th 2016
-	2016 Annual sales	January, 12 th 2017

ABOUT MEDICREA (www.medicrea.com)

The MEDICREA Group specializes in the design, manufacture, and distribution of innovative proprietary technologies devoted exclusively to spinal surgery. Operating in a \$10 billion market, MEDICREA is a small to medium-sized business with 140 employees, including 40 at its MEDICREA USA Corp. subsidiary based in New York City.

The Company enjoys an excellent and ever-improving reputation, and develops unique scientific partnerships with some of the most visionary and creative spine surgeons in France, the UK, and the USA. The products developed and patented by MEDICREA provide neurosurgeons and orthopedic surgeons specializing in the spine with new and less-invasive surgical solutions that are faster and easier to implement than traditional techniques.

MEDICREA has also become **a pioneer and global leader** in the manufacturing of customized implants for personalized spinal surgery with the development of a comprehensive process incorporating the software analysis of each patient, the pre-surgical planning of the surgical strategy, and the production of customized spinal osteosynthesis rods (UNiDTM rod) and lumbar interbody osteosynthesis cages (UNiDTM ALIF cage) that are made to measure by a 3D printer.

The Group's headquarters are based near Lyon, France. It also has an implant and surgical instrument manufacturing facility located in La Rochelle, France, as well as four distribution subsidiaries in the USA, the UK, France and Germany.

Contacts:

MEDICREA Denys Sournac, Chairman and Chief Executive Officer dsournac@medicrea.com Tel: +33 (0)4 72 01 87 87

Fabrice Kilfiger, Chief Financial Officer <u>fkilfiger@medicrea.com</u> Tel: +33 (0)4 72 01 87 87 NewCap Financial Communication / Press and Investor Relations Tristan Roquet Montégon Tel: +33 (0)1 44 71 94 91 medicrea@newcap.fr

MEDICREA is listed on ALTERNEXT Paris ISIN: FR 0004178572 – Ticker: ALMED

